Compare Citius Pharmaceuticals Inc (CTXR) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Target Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Target Corporation trades at $153.9 (market cap $69.17B). The key difference: Target Corporation is far larger — about 3456.8× Citius Pharmaceuticals Inc's market cap, and Target Corporation pays a 3.05% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TGT | |
|---|---|---|
Market Cap | $20.01M | $69.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $152.35 |
52-Week Low | $0.48 | $83.68 |
Enterprise Value | $16.23M | $84.47B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
Target Corporation (TGT) trades at $153.50, up 0.93% today, with strong technical momentum and bullish moving averages. Recent earnings beats and the appointment of a Chief AI Officer highlight operational strength. The stock is near its 52-week high, supported by positive analyst sentiment and consistent dividend payments.
Outlook remains positive with solid fundamentals and growth initiatives, though overbought technical indicators and competitive retail pressures pose risks. Revenue stability and margin improvements are key drivers, but investor caution is warranted near resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
